Clinical efficacy, safety, and cost of nine Chinese patent medicines combined with ACEI/ARB in the treatment of early diabetic kidney disease: A network meta-analysis.

Front Pharmacol · 2022 · PMC9441488 · PMID 36071841

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

likely to be significantno p-value reported

Hence, in this review, we focused on the outcomes most likely to be significant to patients with DKD, for example, UAER, ORR, Scr, 24 h UTP, and AEs.

also in 1,824 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.